Jeffrey Bird Net Worth

The estimated Net Worth of Jeffrey W Bird is at least $14 Million dollars as of 21 August 2018. Jeffrey Bird owns over 390,000 units of Portola Pharmaceuticals stock worth over $13,691,626 and over the last 16 years he sold PTLA stock worth over $0. In addition, he makes $334,427 as Independent Director at Portola Pharmaceuticals.

Jeffrey Bird PTLA stock SEC Form 4 insider trading

Jeffrey has made over 15 trades of the Portola Pharmaceuticals stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 390,000 units of PTLA stock worth $10,077,600 on 21 August 2018.

The largest trade he’s ever made was buying 818,145 units of Portola Pharmaceuticals stock on 30 March 2007 worth over $818,145. On average, Jeffrey trades about 135,734 units every 102 days since 2004. As of 21 August 2018 he still owns at least 449,053 units of Portola Pharmaceuticals stock.

You can see the complete history of Jeffrey Bird stock trades at the bottom of the page.

Jeffrey Bird biography

Dr. Jeffrey W. Bird, M.D. Ph.D. is an Independent Director of the Company. Dr. Bird has been a Managing Director of Sutter Hill Ventures, a venture capital firm. Prior to that time, Dr. Bird was an executive at Gilead Sciences for ten years managing areas including global commercialization. Dr. Bird currently serves as a member of the Board of Directors of Forty Seven, Inc. During the last five years, Dr. Bird also served on the Boards of Directors of Threshold Pharmaceuticals, Inc. and Horizon Pharma Public Limited Company. Dr. Bird also served as CEO of Verinata Health, a commercial stage diagnostics product company. Dr. Bird holds a B.S. in Biological Sciences from Stanford University and a Ph.D. in Cancer Biology and an M.D. from Stanford Medical School. Because of Dr. Bird’s experience in medicine and biology, and because of his experience investing in life science companies and serving as an executive at biopharmaceutical companies, we believe he is able to bring important insights to our Board, Audit Committee and Research and Development Advisory Committee.

What is the salary of Jeffrey Bird?

As the Independent Director of Portola Pharmaceuticals, the total compensation of Jeffrey Bird at Portola Pharmaceuticals is $334,427. There are 9 executives at Portola Pharmaceuticals getting paid more, with Scott Garland having the highest compensation of $5,769,030.

How old is Jeffrey Bird?

Jeffrey Bird is 58, he’s been the Independent Director of Portola Pharmaceuticals since 2003. There are 7 older and 5 younger executives at Portola Pharmaceuticals. The oldest executive at Portola Pharmaceuticals, Inc. is Hollings Renton, 72, who is the Independent Chairman of the Board.

What’s Jeffrey Bird’s mailing address?

Jeffrey’s mailing address filed with the SEC is 755 PAGE MILL ROAD, SUITE A-200, , PALO ALTO, CA, 94304-1005.

Insider trading at Portola Pharmaceuticals

Over the last 11 years, insiders at Portola Pharmaceuticals have traded over $63,947,373 worth of Portola Pharmaceuticals stock and bought 4,311,442 units worth $137,660,828 . The most active insider traders include (Mauritius) Pte Ltd Cairnhi…, James N Topper, and Jeffrey W Bird. On average, Portola Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $2,431,868. The most recent stock trade was executed by Hollings Renton on 1 November 2019, trading 5,000 units of PTLA stock currently worth $45,000.

What does Portola Pharmaceuticals do?

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

What does Portola Pharmaceuticals’s logo look like?

Complete history of Jeffrey Bird stock trades at Corcept Therapeutics, Horizon Therapeutics Plc, Portola Pharmaceuticals, Pure Storage, Yext, Restoration Robotics, and Forty Seven

Portola Pharmaceuticals executives and stock owners

Portola Pharmaceuticals executives and other stock owners filed with the SEC include:

  • Scott Garland, President, Chief Executive Officer
  • John Moriarty, Executive Vice President, General Counsel, Secretary
  • Glenn Brame, Executive Vice President of Technical Operations
  • Ernie Meyer, Chief Human Resource Officer, Executive Vice President
  • Mardi Dier, Chief Financial Officer, Executive Vice President, Business Officer
  • John Johnson, Independent Director
  • Hollings Renton, Independent Chairman of the Board
  • H. Ward Wolff, Independent Director
  • Dennis Fenton, Independent Director
  • Laura Brege, Independent Director
  • Jeffrey Bird, Independent Director
  • David Stump, Independent Director
  • Ted Love, Director
  • Sheldon Koenig, Executive Vice President and Chief Commercial Officer
  • William Lis, Chief Executive Officer
  • (Mauritius) Pte Ltd Cairnhi…,
  • Charles J Homcy, Director
  • Management Pte Ltd Temasek …,
  • Tao Fu, EVP, CBO
  • John H Iii Lawrence, SVP, Chief Medical Officer
  • John T Curnutte, Executive Vice President
  • Robert Califf, Director
  • Farah Champsi, Director
  • (Mauritius) Pte Ltd Maxwell, 10% owner
  • Nicholas Galakatos, Director
  • Jean Jacques Bienaime, Director
  • Russell C Hirsch, Director
  • Peggy V Phillips, Director
  • Jean George, Director
  • James N Topper, Director